PE20001287A1 - Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral - Google Patents
Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoralInfo
- Publication number
- PE20001287A1 PE20001287A1 PE1999001068A PE00106899A PE20001287A1 PE 20001287 A1 PE20001287 A1 PE 20001287A1 PE 1999001068 A PE1999001068 A PE 1999001068A PE 00106899 A PE00106899 A PE 00106899A PE 20001287 A1 PE20001287 A1 PE 20001287A1
- Authority
- PE
- Peru
- Prior art keywords
- dna
- sequence
- muc
- nucleotides
- pharmaceutical composition
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 4
- 230000000259 anti-tumor effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE ADN QUE CODIFICA FRAGMENTOS DE UNA PROTEINA; COMO MUCINA (MUC-1); SOBREEXPRESADA EN CELULAS TUMORALES CON EL FIN DE INDUCIR UNA RESPUESTA INMUNOLOGICA ANTITUMORAL ANTIGENO ESPECIFICA EN COMBINACION CON EXCIPIENTES Y ADYUVANTES; DE PREFERENCIA CONTIENEN 2, 3, 4 MOLECULAS DE ADN, ADN PLASMIDICO, CADA UNA DE LAS CUALES CONTIENE UNA SECUENCIA DE ADN DE 200 A 700 NUCLEOTIDOS; QUE CODIFICA UN FRAGMENTO DE MUCINA (MUC-1); SIENDO LAS SECUENCIAS DE ADN DE 200 A 700 NUCLEOTIDOS, SIENDO CADA SECUENCIA CONTIGUA Y PARCIALMENTE SUPERPUESTA EN 50 A 150 NUCLEOTIDOS EN EL EXTREMO 3` Y/O 5' CON RESPECTO A LA SECUENCIA ADYACENTE; TAMBIEN SE REFIERE A UN ADN PLASMIDICO QUE DERIVA DE LA FUSION DEL VECTOR DE EXPRESION pMRS30 CON LAS SECUENCIAS QUE CODIFICA UN FRAGMENTO DE LA PROTEINA MUC-1 DE 181, 496, 631, 271 DE BASES, LAS QUE ESTAN PRECEDIDAS EN EL EXTREMO 5' POR LA SECUENCIA DE 361 BASES CODIFICADORA DE UBIQUITINA Y UNA PORCION LACL DE ESCHERICHIA COLI, LA COMPOSICION CONTIENE ADEMAS UNA CITOQUINA O UN PLASMIDO CODIFICADOR DE CITOQUINA Y PUEDE SER UTIL COMO VACUNAS DE ADN ANTITUMORAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1998MI002330A IT1303683B1 (it) | 1998-10-30 | 1998-10-30 | Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001287A1 true PE20001287A1 (es) | 2000-12-07 |
Family
ID=11380969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001068A PE20001287A1 (es) | 1998-10-30 | 1999-10-22 | Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1124956A2 (es) |
| JP (1) | JP2002528519A (es) |
| CN (1) | CN1324406A (es) |
| AR (1) | AR020927A1 (es) |
| AU (1) | AU1152200A (es) |
| BG (1) | BG105458A (es) |
| BR (1) | BR9914892A (es) |
| CA (1) | CA2348745A1 (es) |
| CO (1) | CO5231134A1 (es) |
| CZ (1) | CZ20011521A3 (es) |
| EA (1) | EA200100395A1 (es) |
| HU (1) | HUP0103784A2 (es) |
| IT (1) | IT1303683B1 (es) |
| MX (1) | MXPA01004186A (es) |
| PE (1) | PE20001287A1 (es) |
| PL (1) | PL348156A1 (es) |
| SK (1) | SK5712001A3 (es) |
| TR (1) | TR200101141T2 (es) |
| WO (1) | WO2000025827A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| JP2003533181A (ja) * | 2000-02-01 | 2003-11-11 | ジ・オースティン・リサーチ・インスティテュート | ムチン−１誘導抗原および免疫療法におけるその使用 |
| WO2002022685A2 (en) * | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| US20020110841A1 (en) | 2000-12-22 | 2002-08-15 | KUFE Donald W. | Regulation of cell growth by MUC1 |
| BRPI0408774A (pt) * | 2003-03-24 | 2006-03-28 | Scripps Research Inst | vacinas de dna contra crescimento tumoral e seus usos |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| US7871784B2 (en) | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
| US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
| CN106279435B (zh) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 |
| CN113321724B (zh) * | 2021-03-24 | 2022-02-01 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262545B (it) * | 1993-10-25 | 1996-07-02 | Menarini Ricerche Sud S P A A | Sistema di espressione per linee cellulari eucariotiche |
| EP1012276A2 (en) * | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-10-30 IT IT1998MI002330A patent/IT1303683B1/it active
-
1999
- 1999-10-18 CA CA002348745A patent/CA2348745A1/en not_active Abandoned
- 1999-10-18 EA EA200100395A patent/EA200100395A1/ru unknown
- 1999-10-18 MX MXPA01004186A patent/MXPA01004186A/es unknown
- 1999-10-18 PL PL99348156A patent/PL348156A1/xx unknown
- 1999-10-18 CN CN99812745A patent/CN1324406A/zh active Pending
- 1999-10-18 CZ CZ20011521A patent/CZ20011521A3/cs unknown
- 1999-10-18 AU AU11522/00A patent/AU1152200A/en not_active Abandoned
- 1999-10-18 WO PCT/EP1999/007874 patent/WO2000025827A2/en not_active Application Discontinuation
- 1999-10-18 HU HU0103784A patent/HUP0103784A2/hu unknown
- 1999-10-18 SK SK571-2001A patent/SK5712001A3/sk unknown
- 1999-10-18 BR BR9914892-7A patent/BR9914892A/pt not_active IP Right Cessation
- 1999-10-18 EP EP99971329A patent/EP1124956A2/en not_active Withdrawn
- 1999-10-18 TR TR2001/01141T patent/TR200101141T2/xx unknown
- 1999-10-18 JP JP2000579265A patent/JP2002528519A/ja active Pending
- 1999-10-21 AR ARP990105316A patent/AR020927A1/es unknown
- 1999-10-22 PE PE1999001068A patent/PE20001287A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068636A patent/CO5231134A1/es not_active Application Discontinuation
-
2001
- 2001-04-20 BG BG105458A patent/BG105458A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01004186A (es) | 2002-06-04 |
| EA200100395A1 (ru) | 2001-10-22 |
| PL348156A1 (en) | 2002-05-06 |
| ITMI982330A1 (it) | 2000-04-30 |
| CZ20011521A3 (cs) | 2001-10-17 |
| IT1303683B1 (it) | 2001-02-23 |
| JP2002528519A (ja) | 2002-09-03 |
| CO5231134A1 (es) | 2002-12-27 |
| SK5712001A3 (en) | 2002-04-04 |
| ITMI982330A0 (it) | 1998-10-30 |
| BR9914892A (pt) | 2001-07-17 |
| EP1124956A2 (en) | 2001-08-22 |
| HUP0103784A2 (hu) | 2002-02-28 |
| BG105458A (en) | 2002-06-28 |
| CA2348745A1 (en) | 2000-05-11 |
| AR020927A1 (es) | 2002-06-05 |
| TR200101141T2 (tr) | 2001-09-21 |
| WO2000025827A2 (en) | 2000-05-11 |
| CN1324406A (zh) | 2001-11-28 |
| WO2000025827A3 (en) | 2000-08-10 |
| AU1152200A (en) | 2000-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008727A1 (es) | COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | |
| AR020601A1 (es) | Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c | |
| CY1105680T1 (el) | Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου | |
| CY1107702T1 (el) | Πολυπεπτιδια, νουκλεϊκα οξεα στρεπτοκοκκου ομαδας β και θεραπευτικες συνθεσεις και εμβολια αυτων | |
| PE20001287A1 (es) | Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| HUP9901186A2 (hu) | Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra | |
| ES2140418T3 (es) | Flavivirus quimericos y/o flavivirus de crecimiento restringido. | |
| EP1728863A3 (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency | |
| AR014514A1 (es) | Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance | |
| CY1105555T1 (el) | Ανθρωπινα πολυπεπτιδια pellino | |
| NZ500540A (en) | Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae | |
| ES2146214T3 (es) | Vacunas para actinobacillus pleuropneumoniae. | |
| ES2069742T3 (es) | Proteina de la capsida del calicivirus felino y secuencia nucleotida. | |
| BR9812240A (pt) | Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica | |
| AR036793A1 (es) | Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante | |
| DK1219301T3 (da) | Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner | |
| AR027484A1 (es) | Proteina de fusion util en el tratamiento o prevencion del herpes zoster y en la prevencion o tratamiento de infecciones de varicela, adn y arn quecodifican dicha proteina; vectores de expresion y microorganismos recombinantes que comprenden dicho adn o arn; composiciones de vacuna que incluyen dich | |
| BR9815496A (pt) | Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório | |
| WO2003093298A3 (en) | Immunogenic peptides | |
| TW200801034A (en) | Novel sea lice vaccine | |
| PE20000759A1 (es) | Gen de la citocroma oxidasa de hidroquinona del tipo bd | |
| ES2138574T3 (es) | Composicion inmunogenica a base de particulas liberadas por el tumor. | |
| ES2079493T3 (es) | Proteina de membrana externa p1 y peptidos haemophilus influenzae tipo b. | |
| BR9713540A (pt) | Procedimento para a expressão do gene do vìrus da dengue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |